Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex, Inc. (ZYXI) is a Nevada-incorporated medical technology company that develops, manufactures, markets, and sells non-invasive medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. The ZYXI news feed on Stock Titan aggregates company-issued press releases and other coverage that reflect both its operating activities and its financial and regulatory developments.
News about Zynex often highlights its medical device portfolio and corporate events. Company announcements describe its efforts to provide devices that support pain management and rehabilitation and to advance patient monitoring technologies, including multi-parameter and laser-based pulse oximetry. Updates have included submissions of products such as the NiCO laser pulse oximeter for FDA 510(k) review and subsequent strategic decisions to seek commercialization partners through its Zynex Monitoring Solutions subsidiary.
Investors following ZYXI news will also see disclosures related to the company’s financial performance, liquidity, and capital structure. Recent press releases and SEC-related announcements have discussed revenue trends, the impact of a temporary payment suspension from Tricare, restructuring measures, and the company’s evaluation of strategic alternatives with the assistance of external financial advisors and a special committee of the board.
Regulatory and capital markets developments are another key theme in Zynex news. In December 2025, Zynex announced that it had voluntarily entered into Chapter 11 court-supervised financial restructuring and later reported that Nasdaq had determined to delist its common stock as a result of the Chapter 11 cases. These items, along with leadership changes and board appointments, appear in the news flow and provide context on governance and oversight.
By reviewing the ZYXI news page, readers can track company communications on product strategy, restructuring progress, leadership changes, and listing status. This consolidated view helps users understand how Zynex’s medical technology focus intersects with its financial and regulatory path over time.
Zynex reported a 61% year-over-year revenue increase for Q2 2021, totaling $31.0 million. Orders surged by 247%, with a net income of $2.8 million and diluted EPS of $0.08. Adjusted EBITDA reached $4.8 million. The company expects Q3 revenue between $34.5 million and $36.0 million, representing a 72% to 80% increase from Q3 2020. Full-year revenue guidance is lowered to $130.0 million to $137.5 million, still reflecting a 62% to 72% increase from 2020.
Zynex, Inc. (Nasdaq: ZYXI), a leader in non-invasive medical devices, announced its 2021 second quarter earnings investor webcast scheduled for July 29, 2021, at 2:15 p.m. MT (4:15 p.m. ET). The webcast will cover insights into their financial performance and product developments related to pain management and rehabilitation technologies. Participants can register via the provided link. Founded in 1996, Zynex specializes in manufacturing devices such as the NeuroMove, aimed at aiding stroke recovery.
Zynex, Inc. (NASDAQ: ZYXI) reported a remarkable 247% growth in orders year-over-year for Q2 2021, with a 186% increase for the first half of the year. The company confirmed its revenue estimate for Q2 2021 between $31.0 million and $32.5 million, while Adjusted EBITDA is projected to rise to between $4.2 million and $5.2 million, up from prior estimates. For the full year, revenue is expected to be between $135.0 million and $150.0 million, marking a 68% to 87% increase from last year's $80.1 million.
Zynex (NASDAQ: ZYXI) announced its uplisting to the Nasdaq Global Select Market, effective July 14, 2021. This achievement highlights Zynex's strong growth and financial performance, meeting stringent financial, liquidity, and governance criteria. CEO Thomas Sandgaard emphasized the importance of this milestone for enhancing shareholder value. The company specializes in non-invasive medical devices for pain management, stroke rehabilitation, and cardiac monitoring. Zynex's proprietary products include electrotherapy devices and blood volume monitors.
Zynex (NASDAQ: ZYXI), a leader in non-invasive medical devices, announced that its CFO, Dan Moorhead, will present virtually at the Ladenburg Thalmann Annual Healthcare Conference on July 13, 2021. The presentation is scheduled from 12:00 PM to 12:25 PM ET, and Moorhead will also engage in one-on-one meetings with investors. Zynex specializes in devices for pain management, stroke rehabilitation, and cardiac monitoring. Further details can be found on the company's website.
Zynex reported a strong Q1 2021 with a 58% increase in revenue to $24.1 million year-over-year. Orders surged by 140%, yet the company faced a net loss of $0.7 million, marking a GAAP loss per share of $0.02. Gross margins were robust at 76%. The CEO anticipates a profitability ramp-up in Q2 with projected Adjusted EBITDA of over $3 million. Guidance for Q2 revenue is estimated between $31 million and $32.5 million, while full-year revenue is expected between $135 million and $150 million.
Zynex, a medical technology firm, has appointed Donald Gregg as the new Vice President of Sales and Operations for its Monitoring Solutions Division. He is tasked with leading the development and marketing of the CM-1500 Blood Volume Monitor, which received FDA clearance in 2020. CEO Thomas Sandgaard expressed confidence in Gregg's ability to enhance product offerings and sales strategies. The division aims to set new standards for detecting internal bleeding. Gregg's extensive background includes roles at Smith Medical and Medtronic, where he achieved significant sales growth.
Zynex, Inc. (Nasdaq: ZYXI) has announced it will host its first quarter earnings investor webcast on April 29, 2021, at 2:15 p.m. MT (4:15 p.m. ET). The company specializes in non-invasive medical devices for pain management and rehabilitation. Participants can register through the provided link or dial in 10-15 minutes prior to the webcast. Founded in 1996, Zynex designs electrotherapy devices and has developed a proprietary NeuroMove device for stroke recovery.
Zynex, Inc. (NASDAQ: ZYXI) reported a remarkable 140% year-over-year order growth for Q1 2021. The company confirmed revenue estimates for the quarter between $23.0 million and $24.5 million, alongside an estimated Adjusted EBITDA loss of $0.5 million to $1.5 million. For the full year 2021, Zynex anticipates revenues between $135.0 million and $150.0 million, marking a 68% to 87% increase from 2020's revenue of $80.1 million. The company is actively expanding its sales team to promote its prescription-strength NexWave device as a safe alternative for pain management.
Zynex, Inc. (NASDAQ: ZYXI) has announced its relocation to a new corporate headquarters in Englewood, Colorado, expanding its space from 86,000 square feet to 110,754 square feet. The new lease, effective May 3, 2021, spans 84 months and includes an option for an additional 56,158 square feet. CEO Thomas Sandgaard highlighted competitive lease rates and significant rent credits that enhance the company's financial position. This move aligns with Zynex's growth in manufacturing and sales of non-invasive medical devices for pain management and rehabilitation.